---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267745"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:26:14.259788+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated

## Summary
- Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.
- Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.
- Cowen will receive up to 3.0% commission on gross proceeds from sales.
- ATM offering made under existing shelf registration statement (File No. 333-269899).

## SEC filing metadata
- accession: 0001193125-23-267745
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/d282676d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267745
- JSON: https://secwatch.observer/filing/0001193125-23-267745.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267745.txt

## Key facts
- Material Agreements
  Apellis Pharmaceuticals, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC valued at up to $300.0 million (effective 2023-10-31).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $300.0 million
  - Effective: 2023-10-31
  source text: In connection with the entry into the Agreement, on October 31, 2023, the Company terminated its prior Open Market Sale Agreement SM , dated as of January 20, 2022 (the “Prior Agreement”), by and between the Company and Jefferies LLC (“Jefferies”), in accordance with its terms.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm
- Material Agreements
  Apellis Pharmaceuticals, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: up to $300.0 million
  - Effective: 2023-11-01
  source text: On November 1, 2023, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Agreement”) with Cowen and Company, LLC, as agent (“Cowen”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Shares”), from time to time through Cowen (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.